Results

Scientific results are shown on posters at congresses

Generally, RABBIT shows biologic DMARDs to be effective, safe and well tolerated in daily rheumatologic care. Used by experienced rheumatologists, they are a safe treatment option for patients with rheumatoid arthritis, who do not respond adequately to non-biologic DMARDs.

In practice, biologic DMARDs are not prescribed until non-biologic DMARDs fail or are not tolerated. That means that patients for whom biologic DMARDs are indicated differ systematically from patients who are treated with non-biologic DMARDs. Therefore, highly sophisticated statistical methods are required to compare patients on biologic and non-biologic DMARDs.

Here, we will give a short insight into our published results: Original publications

Eingeschlossene Patienten: 23.123 (Stand 01. November 2024)
Amgevita® (Adalimumab)232
Benepali® (Etanercept)1231
Cimzia® (Certolizumab)1038
Enbrel® (Etanercept)2872
Erelzi® (Etanercept)566
Flixabi® (Infliximab)10
Hukyndra® (Adalimumab)8
Hulio® (Adalimumab)258
Humira® (Adalimumab)2910
Hyrimoz® (Adalimumab)239
Idacio® (Adalimumab)66
Imraldi® (Adalimumab)230
Inflectra™ (Infliximab)17
Jyseleca® (Filgotinib)153
Kevzara® (Sarilumab)223
Kineret® (Anakinra)89
MabThera® (Rituximab)1459
Nepexto® (Etanercept)90
Olumiant® (Baricitinib)545
Orencia® (Abatacept)990
Remicade® (Infliximab)762
Remsima® (Infliximab)25
Rinvoq® (Upadacitinib)311
Rixathon® (Rituximab)20
RoActemra® (Tocilizumab)1378
Ruxience® (Rituximab)1
Simponi® (Golimumab)473
Truxima® (Rituximab)2
Tyenne® (Tocilizumab)31
Xeljanz® (Tofacitinib)397
Yuflyma® (Adalimumab)46
Zessly® (Infliximab)2
Kontrollen6449